Aspen Pharmacare Holdings Management
Management criteria checks 4/4
Aspen Pharmacare Holdings' CEO is Stephen Saad, appointed in Jan 2000, has a tenure of 24.92 years. total yearly compensation is ZAR27.30M, comprised of 35.2% salary and 64.8% bonuses, including company stock and options. directly owns 11.82% of the company’s shares, worth ZAR9.12B. The average tenure of the management team and the board of directors is 7.8 years and 5.7 years respectively.
Key information
Stephen Saad
Chief executive officer
R27.3m
Total compensation
| CEO salary percentage | 35.2% |
| CEO tenure | 24.9yrs |
| CEO ownership | 11.8% |
| Management average tenure | 7.8yrs |
| Board average tenure | 5.7yrs |
Recent management updates
We Think Shareholders May Want To Consider A Review Of Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Package
Nov 29
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Recent updates
We Think Shareholders May Want To Consider A Review Of Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Package
Nov 29Aspen Pharmacare Holdings Limited (JSE:APN) Not Lagging Market On Growth Or Pricing
Nov 09Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings
Oct 10Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden
Oct 01Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59
Sep 10We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt
May 08Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable
Mar 05Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Dec 22Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | R27m | R10m | R4b |
| Mar 31 2024 | n/a | n/a | R5b |
| Dec 31 2023 | n/a | n/a | R5b |
| Sep 30 2023 | n/a | n/a | R5b |
| Jun 30 2023 | R24m | R9m | R5b |
| Mar 31 2023 | n/a | n/a | R6b |
| Dec 31 2022 | n/a | n/a | R6b |
| Sep 30 2022 | n/a | n/a | R6b |
| Jun 30 2022 | R23m | R9m | R6b |
| Mar 31 2022 | n/a | n/a | R6b |
| Dec 31 2021 | n/a | n/a | R6b |
| Sep 30 2021 | n/a | n/a | R5b |
| Jun 30 2021 | R24m | R8m | R5b |
| Mar 31 2021 | n/a | n/a | R4b |
| Dec 31 2020 | n/a | n/a | R4b |
| Sep 30 2020 | n/a | n/a | R4b |
| Jun 30 2020 | R23m | R8m | R3b |
| Mar 31 2020 | n/a | n/a | R3b |
| Dec 31 2019 | n/a | n/a | R870m |
| Sep 30 2019 | n/a | n/a | R1b |
| Jun 30 2019 | R14m | R8m | R2b |
| Mar 31 2019 | n/a | n/a | R3b |
| Dec 31 2018 | n/a | n/a | R5b |
| Sep 30 2018 | n/a | n/a | R5b |
| Jun 30 2018 | R17m | R7m | R6b |
Compensation vs Market: Stephen's total compensation ($USD1.49M) is about average for companies of similar size in the ZA market ($USD1.47M).
Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.
CEO
Stephen Saad (60 yo)
24.9yrs
Tenure
R27,303,000
Compensation
Mr. Stephen Bradley Saad, BCom, CA(SA), serves as the Group Chief Executive Officer of Aspen Pharmacare Canada Inc. Mr. Stephen has been the Group Chief Executive Officer of Aspen Pharmacare Holdings Limit...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group CEO & Executive Director | 24.9yrs | R27.30m | 11.82% ZAR 9.1b | |
| Group CFO & Executive Director | 25.9yrs | R16.66m | no data | |
| Group Chief Operations Officer | 11.1yrs | R17.18m | no data | |
| Group Chief Advisor | 2.9yrs | R11.14m | 4.32% ZAR 3.3b | |
| Group Chief Corporate Officer & Executive Director | less than a year | R13.79m | no data | |
| Group Chief Strategic Development Officer | 4.6yrs | R12.81m | no data | |
| Investor Relations Manager | no data | no data | no data | |
| Group Company Secretary & Chief of Staff | less than a year | no data | no data | |
| Regional Chief Executive Officer of Asia Pacific | 10.9yrs | no data | no data | |
| Chief Executive Officer of Aspen Global Incorporated | 7.8yrs | no data | no data | |
| Corporate Affairs & Investor Relations Executive | no data | no data | no data |
7.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: APN's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group CEO & Executive Director | 25.9yrs | R27.30m | 11.82% ZAR 9.1b | |
| Group CFO & Executive Director | 2.9yrs | R16.66m | no data | |
| Group Chief Corporate Officer & Executive Director | less than a year | R13.79m | no data | |
| Lead Independent Non-Executive Director | 5.7yrs | R1.27m | no data | |
| Non-Executive Director | 25.9yrs | R551.00k | no data | |
| Independent Non-Executive Chairman | 12.7yrs | R1.49m | no data | |
| Independent Non-Executive Director | 3yrs | R1.08m | no data | |
| Non-Executive Director | 9.8yrs | R427.00k | no data | |
| Independent Non-Executive Director | 6.4yrs | R1.14m | no data | |
| Independent Non-Executive Director | less than a year | R183.00k | no data | |
| Independent Non-Executive Director | 5.7yrs | R432.00k | no data |
5.7yrs
Average Tenure
57yo
Average Age
Experienced Board: APN's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aspen Pharmacare Holdings Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andre Bekker | Arqaam Capital Research Offshore S.A.L. |
| Boitshepo Seruwe | Avior Capital Markets |
| Simon Mather | Barclays |